China OEM Cinchonidine - L-DOPA Levodopa CAS 59-92-7 API USP BP EP Standard Anti-Parkinson’s Disease High Purity – Ruifu

Short Description:

Name: 5-Bromo-2-Chloro-4′-Ethoxydiphenylmethane

Synonyms: 4-Bromo-1-Chloro-2-(4-Ethoxybenzyl)benzene 

CAS: 461432-23-5

Purity: ≥99.0% (HPLC)

Appearance: White to Pael Yellow Crystalline Powder

Intermediate of Dapagliflozin (CAS: 461432-26-8) in the treatment of type II diabetes

High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Related Video

Feedback (2)

Sticking to the perception of "Creating products of top of the range and earning mates with people today from all over the world", we constantly put the desire of consumers in the first place for 134523-03-8, 86087-23-2, Weight 350.16, We sincerely welcome domestic and foreign merchants who calls, letters asking, or to plants to negotiate, we will offer you quality products and the most enthusiastic service,We look forward to your visit and your cooperation.
China OEM Cinchonidine - L-DOPA Levodopa CAS 59-92-7 API USP BP EP Standard Anti-Parkinson’s Disease High Purity – Ruifu Detail:

Manufacturer with High Purity and Stable Quality
Chemical Name: Levodopa
Synonyms: L-DOPA; 3-(3,4-Dihydroxyphenyl)-L-alanine
CAS: 59-92-7 
Anti-Parkinson’s Disease
API USP/BP/EP/IP Standard, High Quality, Commercial Production

Chemical Name Levodopa
Synonyms L-DOPA; 3-(3,4-Dihydroxyphenyl)-L-alanine
CAS Number 59-92-7
CAT Number RF-API55
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C9H11NO4
Molecular Weight 197.19
Brand Ruifu Chemical
Item Specifications
Appearance White or Milk White Crystalline Powder
Identification Must Positive
Particle Size 100% Pass Through 80
Related Substances
L-Tyrosina ≤0.10%
Levodopareted Compound ≤0.10%
3-Methoxytyrosine ≤0.50%
Total Impurities ≤1.0%
Unknow Impurities ≤0.10%
PH 4.5~7.0
Absorptivity 137~147
Optical Rotation -1.27°~-1.34°
Heavy Metals ≤10ppm
Loss on Drying ≤1.0%
Melting Point 249.5~252.5℃
Heavy Metals ≤20ppm
Sulphated Ash ≤0.10%
Assay 99.0%~100.5%
Test Standard USP/BP/EP/IP Standard
Usage Active Pharmaceutical Ingredient (API); Anti-Parkinson’s Disease

 

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer’s requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

1
2

Levodopa (L-DOPA) used in the treatment of Parkinson’s disease. Levodopa (L-DOPA), the most reliable and effective drug used in the treatment of parkinsonism, can be considered a form of replacement therapy. Levodopa is the biochemical precursor of dopamine. It is used to elevate dopamine levels in the neostriatum of parkinsonian patients. Dopamine itself does not cross the blood-brain barrier and therefore has no CNS effects. However, levodopa, as an amino acid, is transported into the brain by amino acid transport systems, where it is converted to dopamine by the enzyme L-aromatic amino acid decarboxylase.

If levodopa is administered alone, it is extensively metabolized by L-aromatic amino acid decarboxylase in the liver, kidney, and gastrointestinal tract. To prevent this peripheral metabolism, levodopa is coadministered with carbidopa (Sinemet), a peripheral decarboxylase inhibitor. The combination of levodopa with carbidopa lowers the necessary dose of levodopa and reduces peripheral side effects associated with its administration. Levodopa is widely used for treatment of all types of parkinsonism except those associated with antipsychotic drug therapy. However, as parkinsonism progresses, the duration of benefit from each dose of levodopa may shorten (wearing-off effect). Patients can also develop sudden, unpredictable fluctuations between mobility and immobility (on-off effect). In a matter of minutes, a patient enjoying normal or nearly normal mobility may suddenly develop a severe degree of parkinsonism. These symptoms are likely due to the progression of the disease and the loss of striatal dopamine nerve terminals.


Product detail pictures:

China OEM Cinchonidine - L-DOPA Levodopa CAS 59-92-7 API USP BP EP Standard Anti-Parkinson’s Disease High Purity  – Ruifu detail pictures


Related Product Guide:

We aim to find out high quality disfigurement in the generation and provide the most effective services to domestic and abroad clients wholeheartedly for China OEM Cinchonidine - L-DOPA Levodopa CAS 59-92-7 API USP BP EP Standard Anti-Parkinson’s Disease High Purity – Ruifu , The product will supply to all over the world, such as: Portland, Liverpool, India, We look forward to hearing from you, whether you are a returning customer or a new one. We hope you will find what you are looking for here, if not, please contact us immediately. We pride ourselves on top notch customer service and response. Thank you for your business and support!
  • The company can keep up with the changes in this industry market, product updates fast and the price is cheap, this is our second cooperation, it's good.
    5 Stars By Cindy from Brunei - 2018.10.31 10:02
    As a veteran of this industry, we can say that the company can be a leader in the industry, select them is right.
    5 Stars By Hilda from Norway - 2017.01.28 18:53
    Write your message here and send it to us